Eli Lilly and Company (NYSE:LYLY) is one of the Good stocks to buy now. On March 20, Jefferies reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) with a $1,300 price target.
The rating is based on the company’s prescribing data for GLP-1 drugs. Oral Wegovy had approximately 89,300 IMS prescriptions and 76,800 Symphony prescriptions in the 10th week of its launch. The data surpasses comparable launches of Wegovy and Zepbound injectables.
On the other hand, data for other GLP-1 drugs saw declines, including Zepbound which fell 3% to 17,100 prescriptions, Mounjaro fell to 13,100 after a 2% decline, and injectable Wegovy fell 3% to 9,710.
The firm noted that oral Wegovy data is encouraging for Eli Lilly’s Orforglipron, ahead of its PDUFA date of April 10, 2026. The firm projects $2 billion in revenue from Orforglipron by 2026, beating the consensus of $1.55 billion, versus Lilly’s guidance of $80 billion to $83 billion in total revenue.
Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience and other therapies.
While we recognize LLY’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 10 High-Flying Penny Stocks to Buy and 10 cheap stocks to buy for high returns in 2026.
Disclosure: None. Follow Insider Monkey on Google News.